secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-08-15T23:59:59+00:00
Accession:  0000950170-25-109387
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam enters supply agreement with Menarini for obicetrapib products
---------------------------------------------------------------------------

- Supply Agreement dated Aug 12, 2025 with Menarini for obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combo.
- Subsidiary will be exclusive supplier initially; price based on cost of goods sold plus a specified mark-up.
- Parties to initiate manufacturing transfer to Menarini; subsidiary grants non-exclusive license for manufacturing.
- Supply term runs with License Agreement (from June 2022); subsidiary can terminate on 120 days’ notice after transfer or 2 years.
- Either party may terminate for uncured material breach, insolvency, or force majeure exceeding 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025109387/0000950170-25-109387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025109387/nams-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-109387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer